The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions

– Late-breaking data from ORION-1 Phase II study of inclisiran (PCSK9si) will be reviewed by the Company and members of its distinguished advisory board –

PARSIPPANY, N.J.--()--The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis inhibitor. During the call, the Company’s management and inclisiran product teams, as well as members of its distinguished advisory board, will review full safety and efficacy data from ORION-1, with six to nine month follow-up for all patients in the study, which will have been presented earlier in the day in the “Late-Breaking Clinical Trials - Featured Clinical Research 1” session at the American College of Cardiology’s 66th Annual Scientific Session.

“Late-Breaking Clinical Trials - Featured Clinical Research 1”

The conference call may be accessed as follows:

U.S./Canada: (877) 359-9508
International: (224) 357-2393
Conference ID: 60380330

The live webcast may be accessed in the Investors section of The Medicines Company website.

A taped replay of the conference call will be available for approximately one week. The replay may be accessed as follows:

U.S./Canada: (855) 859-2056
International: (404) 537-3406
Conference ID: 60380330

A replay of the webcast will also be available.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.

Contacts

The Medicines Company
Media
Meg Langan
Vice President, 973-290-6319
margaret.langan@themedco.com
or
Investor Relations
Krishna Gorti, M.D., 973-290-6122
Vice President, Investor Relations
krishna.gorti@themedco.com

Recent Stories

RSS feed for The Medicines Company

The Medicines Company